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A study to evaluate the eﬀect of metformin on the immune system was commenced in July 2014.  
Metformin is one of the most commonly prescribed drugs for type 2 diabetes,  and previous studies 
have reported that metformin has an anti-tumor eﬀect.  The aim of this study is to evaluate the eﬃ-
cacy of metformin on the immune system in human cancer patients in vivo.  The primary outcome 
parameter will be the rate change in the population of CD8＋ T cells,  which produce multiple cytokines.
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M alignant tumors are intractable diseases and one of the leading causes of death worldwide.  
Surgery,  chemotherapy and radiotherapy are standard 
therapeutic modalities for various cancers at present.  
However,  the prognosis of cancer patients,  especially 
those with advanced stages,  is not satisfactory.  
Immunotherapy is a means of treating diseases by 
activating or suppressing an immune response,  and it 
has been applied to the treatment of cancers [1,  2].  
However,  previous immunotherapy regimens did not 
show eﬀects comparable to standard treatment 
modalities for various cancers,  although many 
researchers have focused on the relatively low risk of 
adverse events associated with immunotherapy.  
“Cancer vaccination” is one example that was expected 
to have a large anti-tumor eﬀect.  Although this vac-
cine certainly led to an increase in the number of T 
cells,  which were able to attack cancer cells,  neither 
the tumor volume nor the 5-year survival rate were 
aﬀected [3].  Recently,  however,  immune checkpoint 
therapy,  such as PD-1/PD-L1 blockade,  has been 
developed and has shown a drastic eﬀect on several 
malignancies [4].  Thus,  cancer immunotherapy has 
currently come under the spotlight.
　 Recently,  the reason why previous immunotherapy 
regimens did not show satisfactory anti-tumor eﬀects 
has become evident [5-7].  In the tumor microenviron-
ment,  tumor-inﬁltrating CD8＋ T cells are repeatedly 
exposed to tumor antigens.  As a result,  CD8＋ T cells 
become exhausted and lose their anti-tumor activities,  
such as their ability to kill tumor cells,  their prolif-
eration potency,  and the production of several cyto-
kines [6].  Thus,  to achieve eﬀective cancer immuno-
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therapy,  it is necessary to prevent immune exhaustion,  
and this is one of the most important issues to be 
resolved.
　 Metformin is one of the most commonly prescribed 
drugs for type 2 diabetes and has been reported to 
have an anti-tumor eﬀect or to decrease the frequency 
of speciﬁc cancers [8-10].  Two independent meta-
analyses of epidemiological studies concluded that 
metformin was associated with a 30-40  reduction in 
the incidence of various cancers among patients with 
type 2 diabetes,  compared with other treatments,  
indicating that an investigation of the anti-tumor 
mechanisms of metformin and long-term randomized 
controlled trials are warranted [11,  12].  In addition,  
a previous study reported a direct eﬀect of metformin 
against cancer stem cells [13].  The authors have also 
shown an anti-tumor eﬀect of metformin that is depen-
dent on CD8＋ T cells in a mouse model [14].
　 We have already started in vitro studies to evaluate 
the eﬀects of metformin on CD8＋ T cells (approval 
number 1941,  Institutional Review Board of Okayama 
University Hospital: Examination of anti-tumor eﬀects 
of metformin in malignant tumors) and have detected 
that metformin induced the production of multiple 
cytokines in peripheral blood CD8＋ T cells in cancer 
patients in vitro (preliminary data).  We also performed 
an examination to evaluate the eﬀects of metformin on 
CD8＋ T cells in healthy volunteers (approval number 
m12004,  Institutional Review Board of Okayama 
University Hospital: Study about the eﬃcacy of met-
formin to immune function in healthy volunteers) and 
conﬁrmed that there were no severe adverse events 
when metformin was administered to people without 
diabetes (preliminary data).
　 Based on these ﬁndings,  we have commenced an 
interventional study,  the purpose of which is to evalu-
ate the eﬃcacy of metformin on the immune system in 
human cancer patients.  This study protocol was 
approved by the Institutional Review Board of 
Okayama University Hospital in July 2014 (approval 
number m12005),  and patient enrollment started soon 
after approval.  This trial has been registered with the 
UMIN Clinical Trials Registry (UMIN-CTR) as 
UMIN000014689.
Endpoints
　 The objectives of this study are to evaluate the 
eﬃcacy of metformin on immune function and the 
safety of its use in cancer patients,  so as to determine 
whether further investigation is warranted.  The pri-
mary outcome parameter will be the rate change in the 
population of CD8＋ T cells that produce multiple 
cytokines (IFNγ,  TNFα,  and IL-2).  The secondary 
outcome measures will be toxicity and treatment com-
pliance.
Eligibility Criteria
　 All the patients who meet the main inclusion and 
exclusion criteria will be invited for screening.  The 
main inclusion and exclusion criteria of the current 
study are listed in Table 1.
Treatment Methods
　 The current study has been designed as a single-
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Table 1　 Eligibility criteria for this study
Inclusion criteria
　 1. Age of 20 years or older
　 2.  Eastern Cooperative Oncology Group (ECOG) performance 
status of 0-1
　 3. Pathologically proven malignancies
　 4. Written informed consent
　 5.  Subjects who can complain of abnormal and/or subjective 
symptoms if they suﬀer from them during the study
Exclusion criteria
　 1.  Previous medical history of insulin therapy for diabetes mel-
litus
　 2. Previous medical history of lactic acidosis
　 3. Hemodialysis
　 4. Serious hepatic dysfunction
　 5.  Previous medical history of shock status,  heart failure,  cardiac 
infarction,  pulmonary infarction,  or hypoxia
　 6. Drinking habit
　 7.  Dehydration,  Diarrhea or Vomiting with gastrointestinal distur-
bance
　 8.  Previous medical history of severe ketosis,  diabetic coma,  or 
type 1 diabetes
　 9. Severe infection and serious trauma
　10.  Malnutrition,  starvation,  adrenal insuﬃciency,  or pituitary 
gland dysfunction
　11. Pregnancy
　12. Allergy to medicines
　13.  Subjects who have been enrolled in another clinical trial within 
the last 4 months before the administration of metformin and 
who have been treated with any new investigational drugs.
　14.  Other subjects who are judged to be ineligible for this trial by 
the investigator
arm,  prospective,  non-randomized,  open label inter-
ventional trial.  An investigator must obtain the 
patientʼs written informed consent before any screen-
ing or inclusion procedures are performed.  This study 
will be conducted in compliance with the principles of 
the Declaration of Helsinki,  and the protocol has been 
approved by the Institutional Review Board of 
Okayama University Hospital (approval number 
m12005).
　 Patients will take a daily dose of metformin orally 
for 7 to 21 days before receiving the treatment for 
malignancy such as surgery,  chemotherapy and radio-
therapy.  If the patients still keep good condition after 
the treatment for malignancy,  they resume to take 
metformin.  Total duration of administration will be 
less than 2 months (8 weeks).  The initial dose will be 
500mg/day (250mg twice daily),  and the dose will be 
increased up to 1,500mg/day (500mg thrice daily) over 
a few days in the absence of adverse eﬀects.  Because 
three out of ﬁve patients felt nausea when they took 
metformin 1,500mg/day orally,  we amended protocol 
to regarding maximum dose of metformin from 
1,500mg/day (500mg thrice daily) to 1,000mg/day 
(500mg twice daily) on 22th March 2016 (approved by 
the Institutional Review Board of Okayama University 
Hospital,  Table 2).  The dose of metformin will be 
reduced from 500mg to 250mg as a single dose,  from 
250mg thrice daily to 250mg twice daily,  or termi-
nated if the dose of metformin is 250mg twice daily if 
patients exhibit adverse eﬀects such as diarrhea or 
nausea or if they have any diﬃculty continuing to take 
metformin.  The protocol treatment will be terminated 
if patients exhibit Grade-4 non-hematologic toxicities.  
If the patients require examinations using iodinated 
contrast material or invasive therapies such as sur-
gery,  they will stop taking metformin 24h before the 
procedure and will restart taking metformin 48h 
thereafter.  Blood samples and biopsies of tumor 
specimens will be obtained before treatment with 
metformin,  and blood samples will also be obtained 
after the initiation of metformin treatment.  In princi-
ple,  blood samples will be obtained 3 times after the 
treatment for malignancy,  that is,  they will be 
obtained 1 and 3 weeks after the treatment and at the 
point of completion of metformin treatment.  All 
adverse events will be deﬁned according to the 
Common Terminology Criteria for Adverse Events,  
version 4.0.
　 About 20ml blood will be collected from cancer 
patients.  Peripheral blood mononuclear cells (PBMCs) 
were isolated from heparinized blood by density gradi-
ent centrifugation using a Ficoll-PaqueTM (GE 
Healthcare Bio-Sciences,  Uppsala,  Sweden).  1.0-2.0
×106 PBMCs will be suspended in 500 µl of 
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Table 2　 Study design
Enrollment
Duration of administration
4 weeks after
the completion
or stop1-3 weeks
Treatment
for malignancy
(Surgery,
Chemotherapy,
Radiation)
2 weeks
(1 week after
the treatment)
2 weeks
(3 weeks after
the treatment)
2 weeks
(completion)
or stop
Metformin ① ② ③ ③
Physical
examinationa
○ ● ● ● ● ●
Blood samplingb ○ ● ●c ●d ●e
Administration of metformin will be less than 2 months (8 weeks).
a: Physical examination for checking adverse events will be performed in outpatient clinic and at the time of hospital admission.
b: Blood sample will be obtained after taking metformin for more than 1 week.
c: Blood samples will be obtained 1 week after the treatment for malignancy.
d: Blood samples will be obtained 3 weeks after the treatment for malignancy.
e: Blood samples will be obtained at the end of intervention.
　① Metformin: 500 mg/day (250 mg twice daily) for 3 days
　② Metformin: 750 mg/day (250 mg thrice daily) from day 4 to day 7
　③ Metformin: 1,000 mg/day (500 mg twice daily) from day 8
BAMBANKERTM (LYMPHOTEC,  Tokyo,  Japan) 
media,  and the cells are placed in cryotubes for freez-
ing and preservation.  Then,  the cells are frozen and 
preserved at -150 degrees centigrade without pre-
liminary freezing.  After more than 5 samples will be 
collected,  these samples are thawed and cultured with 
or without stimulation by 50 ng/ml PMA (Sigma-
Aldrich,  St. Louis,  MO,  USA)/2µM ionomycin (Sigma-
Aldrich) in a presence of BD Golgi Stop (BD 
Biosciences,  San Jose,  CA,  USA) for 6 h.  Then,  
PBMCs are harvested from culture plate,  resus-
pended in staining buﬀer,  and stained with ﬂuoro-
chrome-conjugated mAb binding for CD8,  PD-1,  
Tim-3,  IFNγ,  TNFα,  and IL-2.  These samples are 
analyzed by BD FACSCantoIITM Flow Cytometer 
(BECTON DICKSON,  Franklin Lakes,  NJ,  USA),  
equipped with three lasers,  having the ability to 
detect eight colors at department of immunology in 
Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Sciences [15].
　 To determine eﬃcacy of metformin,  the rate change 
in the population of CD8＋ T cells capable of producing 
multiple cytokines (IFNγ,  TNFα,  and IL-2) will be 
evaluated.  To evaluate tumor-inﬁltrating lymphocytes 
(TILs) and cancer cells,  we also plan to perform 
immunohistochemistry and to check the number and 
characteristics of TIL by staining for CD3,  CD4,  
CD8,  CD45RA,  Fox-p3,  TUNEL and ALDH1.
Statistical Considerations
　 The planned sample size is 30 patients.  All the 
statistical analyses in this study will be performed 
using EZR (Saitama Medical Center,  Jichi Medical 
University,  Saitama,  Japan),  which is a graphical 
user interface for R (The R Foundation for Statistical 
Computing,  Vienna,  Austria) [16].  Speciﬁcally,  the 
software is a modiﬁed version of R commander 
designed to add statistical functions frequently used in 
biostatistics.  A value of p＜0.05 will be considered 
statistically signiﬁcant.
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